Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study - Top-Institutions - MDSpire

Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study

  • By

  • Jun Fang

  • Siyi Zhong

  • Tielong Wang

  • Kang He

  • Aibo Mu

  • Meiching Ong

  • Yimou Lin

  • Zebin Zhu

  • Ning Wang

  • Jiancheng Wu

  • Zhihao Wang

  • Zhao Li

  • Feng Gao

  • Li Zhuang

  • Zhiyong Guo

  • Shusen Zheng

  • Hao Li

  • Shugeng Zhang

  • Qi Ling

  • June 1, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of California, San Francisco
    University of California, San Francisco

    San Francisco, California

    Key Differentiators

    • Transplant Surgery

  • #2

    Shulan Hospital
    Shulan Hospital

    Shulan, Jilin

    Key Differentiators

    • Transplant Surgery

  • #3

    China Liver Transplant Registry
    China Liver Transplant Registry

    Beijing, Beijing

    Key Differentiators

    • Transplant Surgery

  • #4

    Chinese Society of Biomedical Engineering
    Chinese Society of Biomedical Engineering

    Beijing, Beijing

    Key Differentiators

    • Transplant Surgery

Original Source(s)

Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study

  • by Jun Fang, Siyi Zhong, Tielong Wang, Kang He, Aibo Mu, Meiching Ong, Yimou Lin, Zebin Zhu, Ning Wang, Jiancheng Wu, Zhihao Wang, Zhao Li, Feng Gao, Li Zhuang, Zhiyong Guo, Shusen Zheng, Hao Li, Shugeng Zhang, Qi Ling

  • June 1, 2026

Related Content

Case Report: Tumor regression and neurological recovery in paraplegia from POLD1-mutated hepatocellular carcinoma treated with targeted immunotherapy and electroacupuncture

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

Reduced-intensity versus intensive induction in high-risk acute promyelocytic leukemia: a systematic review and meta-analysis